|
Orthologous residues
|
|
PKD1 (human): S910‑p, PKD1 (mouse): S916‑p, PKD1 (rat): S916‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Disease tissue studied:
breast cancer
|
|
Relevant cell lines - cell types - tissues:
MDA-MB435 (breast cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKD1 (human)
|
pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
arachidonic acid
|
|
|
|
increase
|
|
|
Go 6976
|
arachidonic acid
|
|
|
inhibit treatment-induced increase
|
|
|
Go 6983
|
arachidonic acid
|
|
|
inhibit treatment-induced increase
|
|
|